← Back to Calendar
Live Company Data
NGM
Updated
just now
· Data: FMP
Current Price
$53.50
+236.48%
+$37.60 today
Day: $53.10 – $56.40
Market Cap
N/A
Shares out: 70.84M
Float: 164.53M
52-Week Range
Current price is at 48% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Obesity / overweight (oral GLP-1 receptor agonist)
Key Notes
Phase 2 ACCESS II positive topline data released March 16, 2026. Aleniglipron (renamed from GSBR-1290) showed up to 16.3% weight loss at 44 weeks and 16.2% at 56 weeks. AE-related discontinuations reduced to just 2.0–3.4% using new 2.5mg starting dose (vs higher rates previously). No drug-induced liver injury or QTc prolongation in >625 participants. End-of-Phase 2 FDA Type B meeting planned Q2 2026; Phase 3 initiation on track for 2H 2026. Oral non-peptide GLP-1 agonist competing with Lilly orforglipron. Next catalyst: Phase 3 design confirmation at Type B meeting.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.